EP3628749A1 — Ntrk2 fusions
Assigned to Blueprint Medicines Corp · Expires 2020-04-01 · 6y expired
What this patent protects
The invention provides to NTRK (Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with NTRK fusions, such as …
USPTO Abstract
The invention provides to NTRK (Neurotrophic Tyrosine Receptor Kinase) gene fusions, NTRK fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with NTRK fusions, such as conditions mediated by aberrant NTRK expression or activity, or overexpression of NTRK.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.